Brought to you by 
Perrigo gets rights to sell generic form of Nycomed's Cutivate lotion
06 Jun 2011
Executive Summary
In its second settlement agreement this month for Cutivate (fluticasone), Nycomed US Inc. (a division of Nycomed International Management GMBH) has granted Perrigo Co. the right to launch a generic version of the drug for atopic dermatitis on September 22, 2012, or earlier pending certain circumstances. Nycomed, which gained FDA approval for Cutivate in early 2005, also licensed Glenmark Generics rights to market a generic version of the drug in March 2012. Cutivate has annual sales of about $50mm.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Perrigo gets rights to sell generic form of Nycomed's Cutivate lotion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice